Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer trial seeks same results with fewer side effects

NCT ID NCT01896479

Ongoing Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

Summary

This study aims to see if a lower daily dose (60 mg) of the cancer drug cabozantinib works as well as the standard higher dose (140 mg) for people with advanced medullary thyroid cancer that is getting worse. Researchers want to find out if the lower dose can control the cancer for a similar length of time while causing fewer side effects. The trial involves about 250 participants and compares the two doses directly.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEDULLARY THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Study site

    St Leonards, New South Wales, 2065, Australia

  • Study site

    Herston, Queensland, 4006, Australia

  • Study site

    Kurralta Park, South Australia, 5037, Australia

  • Study site

    Parkville, Victoria, 3050, Australia

  • Study site

    Québec, Quebec, JIH 5N4, Canada

  • Study site

    Toronto, M5G 2M9, Canada

  • Study site

    Osijek, 31000, Croatia

  • Study site

    Zagreb, 10000, Croatia

  • Study site

    Zagreb, 1000, Croatia

  • Study site

    Bordeaux, Gironde, 33076, France

  • Study site

    Angers, Maine-et-Loire, 49933, France

  • Study site

    Lyon, Rhône, 69373, France

  • Study site

    Villejuif, Val-de-Marne, 94805, France

  • Study site

    Dijon, 21079, France

  • Study site

    Paris, 75013, France

  • Study site

    Strasbourg, 67065, France

  • Study site

    Budapest, 1088, Hungary

  • Study site

    Debrecen, 4032, Hungary

  • Study site

    Jerusalem, 91120, Israel

  • Study site

    Petah Tikva, 49100, Israel

  • Study site

    Safed, 13100, Israel

  • Study site

    Catania, CT, 95124, Italy

  • Study site

    Roma, RM, 00161, Italy

  • Study site

    Siena, SI, 53100, Italy

  • Study site

    Pisa, Tuscany, 56124, Italy

  • Study site

    Milan, 20133, Italy

  • Study site

    Padua, 35138, Italy

  • Study site

    Torino, 10153, Italy

  • Study site

    Amsterdam, North Holland, 1066 CX, Netherlands

  • Study site

    Leiden, South Holland, 2333 ZA, Netherlands

  • Study site

    Groningen, 9713 GZ, Netherlands

  • Study site

    Poznan, Greater Poland Voivodeship, 60-355, Poland

  • Study site

    Gliwice, Silesian Voivodeship, 44-100, Poland

  • Study site

    Bucharest, 10825, Romania

  • Study site

    Bucharest, 11863, Romania

  • Study site

    Cluj-Napoca, 400058, Romania

  • Study site

    Timișoara, 300723, Romania

  • Study site

    Novosibirsk, 630068, Russia

  • Study site

    Obninsk, 249036, Russia

  • Study site

    Saint Petersburg, 197089, Russia

  • Study site

    Yaroslavl, 150040, Russia

  • Study site

    Goyang, Gyeonggido, 410769, South Korea

  • Study site

    Seoul, 110744, South Korea

  • Study site

    Seoul, 135-710, South Korea

  • Study site

    Barcelona, 08035, Spain

  • Study site

    Madrid, 28034, Spain

  • Study site

    Madrid, 28046, Spain

  • Study site

    Lund, Skane Ian, SE-22185, Sweden

  • Study site

    Uppsala, Uppsala Ian, 75185, Sweden

Conditions

Explore the condition pages connected to this study.

MEDULLARY THYROID CANCER